Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Glioblastoma Multiforme|Brain Neoplasms|Gastroesophageal Adenocarcinoma|Pancreatic Ductal Adenocarcinoma
Interventions: DRUG: 68Ga-FF58
Sponsor: Novartis Pharmaceuticals